Bank of Nova Scotia
ANRO icon

Bank of Nova Scotia’s Alto Neuroscience ANRO Stock Holding History

Bank of Nova Scotia’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Buy
+14,400
New +$333K ﹤0.01% 995

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bank of Nova Scotia's ANRO Position: Q2 2026 in Review

Bank of Nova Scotia opened a new position in Alto Neuroscience (ANRO) in Q2 2026: 14,400 shares worth $380K. The stake represents ﹤0.01% of the portfolio and ranks #995 among its holdings.

114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Bank of Nova Scotia held 14,400 shares of Alto Neuroscience worth $380K as of Q2 2026.
  • Alto Neuroscience was a new Bank of Nova Scotia position in Q2 2026.
  • Alto Neuroscience made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #995 holding.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.